Literature DB >> 35350254

Spondylodiscitis associated with skin lesions caused by Rhizopus in a patient with systemic lupus erythematosus.

Larissa Silva de Saboya1, Moara Alves Santa Bárbara Borges1,2, Diego Gonçalves Camargo1,2, Maria Auxiliadora de Paula Carneiro Cysneiros1, Murilo Eugênio Oliveira1, Adriana Oliveira Guilarde1,2.   

Abstract

Mucormycosis is a serious and rare fungal disease caused by opportunistic fungi of the zygomycete class, order Mucorales. The main clinical presentations are rhinocerebral, pulmonary, cutaneous, gastrointestinal, and disseminated infections. There are few reports in the literature of spondylodiscitis caused by mucormycosis. We report a 53-year-old male patient presenting with subcutaneous nodules and severe low back pain radiating to the lower limbs. The patient had systemic lupus erythematosus (SLE) for 8 years and corticoid-induced diabetes. He had been using 60 mg/day of prednisone in the last year, with a recent pulse therapy regimen with methylprednisolone and cyclophosphamide to control the renal dysfunction. Nuclear magnetic resonance (NMR) of the spine showed spondylodiscitis. The patient underwent spinal arthrodesis and lesion biopsy. The histopathological study of the vertebra reported a necro suppurative inflammation with numerous fungal structures described as a wide range of hyaline hyphae. The histopathology of the cutaneous nodule exhibited an extensive suppurative lesion centered on the subcutaneous tissue, associated with a large amount of hyphae, similar to that found in the spinal lesion, suggestive of mucormycosis. The fungal culture showed the growth of Rhizopus spp. Treatment was performed with amphotericin B lipid complex 5 mg/kg/day for 60 days. After antifungal treatment, there was a progressive reduction in the number of subcutaneous nodules and total improvement of the patient's low back pain, with recovery of his gait. At the 18-month outpatient visit follow-up, the patient was stable and without recurrence. In our case, timely diagnosis enabled the removal of the osteoarticular focus and the targeted therapy resulted in a satisfactory clinical response, without sequelae or complications, despite the patient's underlying immunosuppressed status.
Copyright © 2022 InfezMed.

Entities:  

Keywords:  Rhizopus; mucormycosis; spondylodiscitis; systemic lupus erythematosus

Year:  2022        PMID: 35350254      PMCID: PMC8929733          DOI: 10.53854/liim-3001-17

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  15 in total

1.  Mucormycosis spondylodiscitis after lumbar disc puncture.

Authors:  Fei Chen; Guohua Lü; Yijun Kang; Zeming Ma; Chang Lu; Bin Wang; Jin Li; Jun Liu; Haisheng Li
Journal:  Eur Spine J       Date:  2005-11-18       Impact factor: 3.134

2.  Mucormycosis of petrous bone in an allogeneic stem cell transplant recipient.

Authors:  M M Oo; L A Kutteh; O N Koc; M Strauss; H M Lazarus
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

Review 3.  Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.

Authors:  Treavor T Riley; Christina A Muzny; Edwin Swiatlo; Davey P Legendre
Journal:  Ann Pharmacother       Date:  2016-06-15       Impact factor: 3.154

Review 4.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

5.  Vertebral osteomyelitis and epidural abcess due to mucormycosis, a case report.

Authors:  O J Buruma; H Craane; M W Kunst
Journal:  Clin Neurol Neurosurg       Date:  1979       Impact factor: 1.876

6.  The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports.

Authors:  W Jeong; C Keighley; R Wolfe; W L Lee; M A Slavin; D C M Kong; S C-A Chen
Journal:  Clin Microbiol Infect       Date:  2018-07-21       Impact factor: 8.067

7.  Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl.

Authors:  Luigi Tarani; Francesco Costantino; Gundula Notheis; Uwe Wintergerst; Mario Venditti; Claudio Di Biasi; Donata Friederici; Anna Maria Pasquino
Journal:  Pediatr Diabetes       Date:  2009-09-25       Impact factor: 4.866

8.  Posaconazole as first line treatment for disseminated zygomycosis.

Authors:  Trisha Peel; John Daffy; Karin Thursky; Peter Stanley; Kirsty Buising
Journal:  Mycoses       Date:  2008-04-16       Impact factor: 4.377

Review 9.  Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment.

Authors:  R M Prabhu; R Patel
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 10.  Severe osteomyelitis due to the zygomycete Apophysomyces elegans.

Authors:  J F Meis; B J Kullberg; M Pruszczynski; R P Veth
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.